Combination of KRASG12C (ON) and SHP2 inhibitors overcomes adaptive resistance and enhances anti-tumour immunity
P Anastasiou, J Boumelha, E Mugarza… - European Journal of …, 2022 - ejcancer.com
… higher potency for inhibition of cell viability than the KRAS G12C (OFF) inhibitor MRTX849 in
… in RAS pathway reactivation which was blocked upon coincubation with the SHP2 inhibitor …
… in RAS pathway reactivation which was blocked upon coincubation with the SHP2 inhibitor …
[HTML][HTML] SHP2 as a primordial epigenetic enzyme expunges histone H3 pTyr-54 to amend androgen receptor homeostasis
S Chouhan, D Sridaran, C Weimholt, J Luo, T Li… - Nature …, 2024 - nature.com
… mutants of SHP2 may activate other signaling pathway that is … AR reactivation could partly
compensate for the loss of SHP2 … upon treatment with ACK1 and SHP2 inhibitor appears to be …
compensate for the loss of SHP2 … upon treatment with ACK1 and SHP2 inhibitor appears to be …
SHP-2 expression negatively regulates NK cell function
AK Purdy, KS Campbell - The Journal of Immunology, 2009 - journals.aai.org
… After transfer, membranes were air-dried, reactivated with methanol, washed once with …
conclude that SHP-2 is playing an inhibitory role at the level of pathways controlling cytoskeleton …
conclude that SHP-2 is playing an inhibitory role at the level of pathways controlling cytoskeleton …
[PDF][PDF] sHP2 Inhibitors
P Torres-Ayuso, J Brognard - 2018 - researchgate.net
… Multiple attempts to therapeutically target RAS directly or pathways … on SHP2, and
reactivation of downstream signals. Inhibition of both MEK and SHP2 abrogates MEK inhibitor–…
reactivation of downstream signals. Inhibition of both MEK and SHP2 abrogates MEK inhibitor–…
From pyrazolones to azaindoles: evolution of active-site SHP2 inhibitors based on scaffold hopping and bioisosteric replacement
Y Mostinski, GJJE Heynen… - Journal of medicinal …, 2020 - ACS Publications
… The tyrosine phosphatase SHP2 controls the activity of pivotal signaling pathways, including
MAPK… Inhibition of ERK feedback reactivation is sustained after 48 h compared to PLX4032 …
MAPK… Inhibition of ERK feedback reactivation is sustained after 48 h compared to PLX4032 …
SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
M Meem - 2022 - dspace.bracu.ac.bd
… recent advances made with SHP2 inhibitors as a targeted therapy … of cancer treatment based
on SHP2 inhibition. An additional … due to the reactivation of the MAPK pathway for negative …
on SHP2 inhibition. An additional … due to the reactivation of the MAPK pathway for negative …
Combination mTOR and SHP2 inhibitor treatment of lymphatic malformation endothelial cells
JK Wolter, I Valencia-Sama, AJ Osborn, EJ Propst… - Microvascular …, 2022 - Elsevier
… inhibitors are being investigated for treatment of various … determine the impact of SHP2
inhibition in combination with rapamycin … re-activation of AKT, and that targeting the RAS pathway …
inhibition in combination with rapamycin … re-activation of AKT, and that targeting the RAS pathway …
[PDF][PDF] Sulforaphane-mediated inhibition of SHP2 as a potential pharmacotherapy for Noonan syndrome
J Smith, E Schroder, O Prysyazhna, H Cho, M Mayr… - 2019 - kclpure.kcl.ac.uk
… would inhibit SHP2 … SHP2 activity was also attenuated in the spleen of both WT and NS
mice, strongly suggesting this therapeutic action of SFX-01 was mediated by inhibition of SHP2 …
mice, strongly suggesting this therapeutic action of SFX-01 was mediated by inhibition of SHP2 …
[HTML][HTML] Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation
Y Kano, T Gebregiworgis, CB Marshall… - Nature …, 2019 - nature.com
… Protein tyrosine phosphatase SHP2 promotes RAF-to-MAPK signaling pathway and is an …
reactivates downstream signaling 6 . We further showed that pharmacologic inhibition of SHP2 …
reactivates downstream signaling 6 . We further showed that pharmacologic inhibition of SHP2 …
ERAS-007 (ERK inhibitor)+ ERAS-601 (SHP2 inhibitor) exhibit nonclinical combination activity across KRAS mutated NSCLC, CRC, and PDAC tumor models
L Martin, ED Lew, R Patel, J Oh, J Zhang, R Nevarez… - Cancer Research, 2022 - AACR
… pathway nodes has the potential to more robustly prevent reactivation relative to inhibition
… We are currently exploring the combination of an inhibitor of an upstream node, SHP2, with …
… We are currently exploring the combination of an inhibitor of an upstream node, SHP2, with …